Allergy Therapeutics has announced that its Phase II clinical trial investigating the dosing of PQ Grass has received clinical trial application (CTA) approval for various European countries as planned. With the study expected to begin ‘imminently’, we expect a 2H 2018 read-out of results which should pave the way towards the late-stage clinical development cycle for PQ Grass in the US. With momentum building and prelims expected later this month, we repeat our Buy recommendation.
